100
Participants
Start Date
June 6, 2023
Primary Completion Date
September 30, 2026
Study Completion Date
September 30, 2026
BMS-986449
Specified dose on specified days
Nivolumab
Specified dose on specified days
Local Institution - 0016, Brussels
Local Institution - 0017, Ghent
Local Institution - 0022, Lake Success
Local Institution - 0004, Marseille
Local Institution - 0023, Rozzano
Local Institution - 0026, Bergamo
Local Institution - 0014, Madrid
Local Institution - 0011, Madrid
Local Institution - 0015, Málaga
Local Institution - 0012, Pamplona
Local Institution - 0003, Bordeaux
Local Institution - 0024, Siena
Local Institution - 0021, Los Angeles
Local Institution - 0002, Villejuif
Local Institution - 0007, New Haven
Local Institution - 0010, Hackensack
Local Institution - 0025, Roma
Local Institution - 0030, Amsterdam
Local Institution - 0018, Groningen
Local Institution - 0013, Badalona
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY